Bioequivalence study of BHV-0223 in patients with amyotrophic lateral sclerosis
Phase of Trial: Phase I
Latest Information Update: 09 Jan 2018
At a glance
- Drugs Riluzole (Primary) ; Riluzole
- Indications Amyotrophic lateral sclerosis
- Focus Pharmacokinetics
- 09 Jan 2018 According to a Biohaven Pharmaceutical Holding Company, based on the results, the company plans to submit a new drug application (NDA) requesting BHV-0223 to be approved in the first half of 2018.
- 09 Jan 2018 Top-line results (n=138) published in a Biohaven Pharmaceutical Holding Company media release.
- 06 Nov 2017 According to a Biohaven Pharmaceuticals media release, company today announced that the first subject was dosed in this study.